| Primary |
| Product Used For Unknown Indication |
25.5% |
| Sepsis |
8.0% |
| Osteitis |
6.4% |
| Osteomyelitis |
5.9% |
| Endocarditis |
5.3% |
| Infection |
5.3% |
| Tuberculosis |
5.3% |
| Meningitis Aseptic |
4.8% |
| Drug Use For Unknown Indication |
4.3% |
| Septic Arthritis |
4.3% |
| Endocarditis Staphylococcal |
3.7% |
| Abscess |
3.2% |
| Pain |
3.2% |
| Haematoma Infection |
2.7% |
| Skin Ulcer |
2.7% |
| Intervertebral Discitis |
2.1% |
| Meningitis Tuberculous |
2.1% |
| Pulmonary Tuberculosis |
2.1% |
| Antibiotic Therapy |
1.6% |
| Device Related Infection |
1.6% |
|
| Renal Failure Acute |
14.7% |
| Thrombocytopenia |
14.7% |
| Jaundice |
8.8% |
| Drug Interaction |
5.9% |
| Pyrexia |
5.9% |
| Rash |
5.9% |
| Toxic Skin Eruption |
5.9% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.9% |
| Eosinophilia |
2.9% |
| Epilepsy |
2.9% |
| Gynaecomastia |
2.9% |
| Hepatitis Fulminant |
2.9% |
| Hepatocellular Injury |
2.9% |
| Hyperuricaemia |
2.9% |
| Hyponatraemia |
2.9% |
| International Normalised Ratio Decreased |
2.9% |
| Lactic Acidosis |
2.9% |
| Lipase Increased |
2.9% |
| Liver Disorder |
2.9% |
| Mixed Liver Injury |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
24.9% |
| Arthritis Bacterial |
10.9% |
| Staphylococcal Infection |
9.3% |
| Infection |
8.0% |
| Osteomyelitis |
5.8% |
| Hypertension |
4.8% |
| Endocarditis |
4.5% |
| Abscess |
3.8% |
| Sepsis |
3.2% |
| Meningitis Aseptic |
2.9% |
| Mycobacterial Infection |
2.9% |
| Arthritis Infective |
2.6% |
| Chronic Obstructive Pulmonary Disease |
2.6% |
| Atrial Fibrillation |
2.2% |
| Diabetic Foot |
2.2% |
| Drug Use For Unknown Indication |
1.9% |
| Hiv Infection |
1.9% |
| Hyperuricaemia |
1.9% |
| Hypothyroidism |
1.9% |
| Ulcer |
1.9% |
|
| Transaminases Increased |
16.7% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
13.0% |
| Hepatocellular Injury |
11.1% |
| Acquired Haemophilia |
5.6% |
| Thrombocytopenia |
5.6% |
| Urticaria |
5.6% |
| Hyperbilirubinaemia |
3.7% |
| Hyperhidrosis |
3.7% |
| Nephropathy Toxic |
3.7% |
| Rash |
3.7% |
| Rash Maculo-papular |
3.7% |
| Renal Failure Acute |
3.7% |
| Stevens-johnson Syndrome |
3.7% |
| Toxic Skin Eruption |
3.7% |
| Urinary Incontinence |
3.7% |
| Hepatic Failure |
1.9% |
| Hepatitis |
1.9% |
| Hepatitis Cholestatic |
1.9% |
| Incorrect Drug Administration Duration |
1.9% |
| International Normalised Ratio Decreased |
1.9% |
|
| Concomitant |
| Hiv Infection |
20.7% |
| Product Used For Unknown Indication |
17.1% |
| Osteitis |
13.5% |
| Tuberculosis |
6.3% |
| Staphylococcal Infection |
4.5% |
| Antibiotic Therapy |
3.6% |
| Infection |
3.6% |
| Pain |
3.6% |
| Prophylaxis |
3.6% |
| Pulmonary Tuberculosis |
3.6% |
| Sepsis |
3.6% |
| Breast Cancer Metastatic |
1.8% |
| Cardiac Arrhythmia |
1.8% |
| Dementia |
1.8% |
| Depression |
1.8% |
| Device Related Infection |
1.8% |
| Endocarditis Staphylococcal |
1.8% |
| Hypertension |
1.8% |
| Intervertebral Discitis |
1.8% |
| Myelodysplastic Syndrome |
1.8% |
|
| Pyrexia |
10.3% |
| Thrombocytopenia |
10.3% |
| Hyponatraemia |
6.9% |
| Rash Maculo-papular |
6.9% |
| Renal Failure Acute |
6.9% |
| Toxic Skin Eruption |
6.9% |
| Tuberculosis |
6.9% |
| Acute Generalised Exanthematous Pustulosis |
3.4% |
| Cholelithiasis |
3.4% |
| Convulsion |
3.4% |
| Deafness Unilateral |
3.4% |
| Erectile Dysfunction |
3.4% |
| Hypersensitivity |
3.4% |
| Pruritus |
3.4% |
| Rash |
3.4% |
| Rash Morbilliform |
3.4% |
| Renal Cell Carcinoma Stage Iii |
3.4% |
| Renal Failure Chronic |
3.4% |
| Rhabdomyolysis |
3.4% |
| Systemic Candida |
3.4% |
|
| Interacting |
| Product Used For Unknown Indication |
58.8% |
| Device Related Infection |
11.8% |
| Prophylaxis |
11.8% |
| Epilepsy |
5.9% |
| Hypothyroidism |
5.9% |
| Prophylaxis Against Transplant Rejection |
5.9% |
|
| Drug Interaction |
25.0% |
| Drug Level Below Therapeutic |
25.0% |
| Renal Failure Acute |
25.0% |
| Transplant Rejection |
25.0% |
|
